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Abstract 
 We recently generated glutathione S-transferase (GST) A3 knockout (KO) mice as a 
novel model to study the risk factors for liver cancer. GSTA3 KO mice are sensitive to 
the acute cytotoxic and genotoxic effects of aflatoxin B1 (AFB1), confirming the crucial 
role of GSTA3 in resistance to AFB1. We now report histopathological changes, tumor 
formation, biochemical changes and gender response following AFB1 treatment as well 
as the contribution of oxidative stress. Using a protocol of weekly 0.5 mg AFB1/kg 
administration, we observed extensive oval (liver stem) cell (OC) proliferation within 1-3 
weeks followed by microvesicular lipidosis, megahepatocytes, nuclear inclusions, 
cholangiomas, and small nodules. Male and female GSTA3 KO mice treated with 12 
and 24 weekly AFB1 injections followed by a rest period of 12 and 6 months, 
respectively, all had grossly distorted livers with macro- and microscopic cysts, 
hepatocellular nodules, cholangiomas and cholangiocarcinomas and OC proliferation. 
We postulate that the prolonged AFB1 treatment leads to inhibition of hepatocyte 
proliferation which is compensated by OC proliferation and eventually formation of 
cholangiocarcinoma (CCA).  At low-dose AFB1, male KO mice showed less extensive 
acute liver injury, OC proliferation, and AFB1-DNA adducts than female KO mice. There 
were no significant compensatory changes in KO mice GST subunits, GST enzymatic 
activity, epoxide hydrolase, or CYP1A2 and CYP3A11 levels.  Finally, there was a 
modest increase in F2-isoprostane and isofuran in KO mice that confirmed putative 
GSTA3 hydroperoxidase activity in vivo for the first time.  
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Summary 
We’ve extended characterization of our novel GSTA3 knockout mice toward better 
understanding human liver cancer. Our results demonstrate extensive oval cell 
proliferation, numerous pathological changes, tumor formation, and increased female 
susceptibility following aflatoxin and CCl4 exposure in GSTA3 knockouts. 
 
Introduction 
 Aflatoxin B1 (AFB1) is a potent hepatotoxin and hepatocarcinogen for humans and 
most other mammalian species, but adult mice are highly resistant (1).  AFB1 is 
produced by the mold Aspergillus flavus, which typically grows on groundnuts, grain and 
maize that are commonly consumed by mice. This dietary exposure is one reason that 
mice may have developed resistance to the mycotoxin. In both human and mice, AFB1 
is metabolized by cytochromes P450 (CYP) to a reactive AFB1-epoxide that can cause 
genotoxic damage by binding with DNA at the N-7 atom of guanine (2).  Once formed, 
the AFB1-epoxide may be detoxified by conjugation with reduced glutathione through 
the catalytic actions of members of the cytosolic family of glutathione S-transferase 
(GST) enzymes.  The glutathione conjugates of AFB1-epoxides are excreted in urine as 
water soluble aflatoxin mercapturic acids (AFB1-NAC) (3). The intrinsic resistance of 
mice to AFB1 may be attributed to a relatively low ability of CYP isoenzymes to form the 
reactive epoxide and/or high ability of GST isoenzymes to form glutathione conjugates. 
Mice constitutively express a hepatic class Alpha GST subunit, GSTA3 (with the dimeric 
enzyme called A3-3), which exhibits high activity towards AFB1-epoxide and is thought 
to contribute to the resistant phenotype (4). Interestingly, the rat, which is sensitive to 
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AFB1 hepatocarcinogenesis, possesses an inducible class Alpha GST that is similar to 
mouse GSTA3, and when induced by chemopreventive agents confers resistance to the 
mycotoxin (5).  
 Newborn mice are substantially more susceptible to AFB1 hepatocarcinogenesis 
than adult animals (6). We found that newborn mice have very low hepatic GST levels 
and high hepatic AFB1 DNA adduction when compared to their adult counterparts (1). 
Thus, we hypothesized that the resistance of adult mice to AFB1 is related to the 
relatively high levels of expression of GSTA3. To test this, we constructed a GSTA3 
knockout (KO) mouse (7). In contrast to resistant adult wild-type (WT) mice, adult 
GSTA3 KO mice harboring disruption of the GSTA3 gene exhibited acute cytotoxicity 
and genotoxicity upon exposure to AFB1. Specifically, AFB1-treated GSTA3 KO mice 
acquired ≥100-fold more AFB1-N7-DNA adducts in their livers than did similarly treated 
WT mice, and GSTA3 KO mice died of massive hepatic necrosis at doses of AFB1 that 
exert minimal toxicity on WT mice (7).  These results indicated that GSTA3 is a primary 
determinant of intrinsic resistance to AFB1 in the mouse. Importantly, humans lack a 
GST isoenzyme with the same high catalytic activity towards AFB1-epoxide as mouse 
GST A3-3.  Thus, the GSTA3 KO mice may be considered “humanized” in regard to 
AFB1 metabolism.  
Oval cells (OCs) are thought to be putative liver stem cells that may give rise to 
hepatocellular and cholangiocellular carcinomas (8,9). Although there are reports of 
induction of OC proliferation in mice (10), the extent is far less than in rats and the 
significance of OCs in mice in liver regeneration and as precursors of liver cancer is not 
clear. They are seen in human livers associated with severe tissue damage and can be 
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induced experimentally in several species, mostly in various models in rats and, less 
frequently and at very much reduced numbers, in mice (11,12). When seen in the 
context of carcinogen exposure, OC are thought to function as cancer stem cells that 
are capable of developing into hepatocellular and/or cholangiocellular carcinomas (8, 
9,13). Thus, the study of OCs in animal models is important from two perspectives: 1, 
as cancer stem cells, as the cells of origin of liver cancer, and; 2, as normal stem cells, 
for their potential use in regeneration therapy.  
 In the present paper, we assess the effects of loss of GSTA3 on AFB1-induced 
toxicity by measuring histopathological changes, tumor formation, gender response,   
AFB1 metabolism, OC response, AFB1-DNA adduct formation, GST enzyme activity, 
and the extent of oxidative damage in liver tissues.  Our results provide new insights 
into the response of our new humanized KO mouse model to carcinogen treatment 
toward better understanding liver cancer.  
 
Materials and methods 
 Mice.  Three-month old female and male GSTA3 KO mice were injected i.p. with the 
appropriate dosage of AFB1 or carbon tetrachloride (CCl4) (see results for doses used 
in various experiments).  AFB1 (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO 
and administered to mice in a volume of 100 µl per 30 grams body weight).  CCl4 was 
obtained from Sigma (≥95 5%) and administered in corn oil to final 1 ml/kg body weight.   
Mice were then euthanized on the appropriate days after injection of AFB1. At necropsy, 
liver and other tissues were collected and fixed in formalin, and then processed, 
embedded in paraffin, sectioned and stained with H&E. Histological evaluation of all 
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tissues was undertaken by Dr. Sell, a certified pathologist. All animal studies were 
approved by the Wadsworth Center Institutional Animal Care and Use Committee (Dr. 
Sell, PI; Protocol #15-370), and animals handled and treated according to the 
regulations set forth in the approved Wadsworth Center Institutional Animal Care and 
Use Protocol. 
 Immunohistochemistry. A6 and cytokeratin (oval cells).  Formalin fixed and 
paraffin embedded tissues were cut at 5 µm and antigens retrieved by immersing slides 
in trypsin buffer (0.1% trypsin, 0.1% CaCl2 in PBS) with addition of proteinase K (25 
µg/ml) for 15 minutes at 37°C. Tissues were then treated with 0.3% hydrogen peroxide 
in 100% methanol for 15 minutes and blocking serum (3% normal goat serum in PBS 
containing 1% BSA) for 30 minutes before adding primary monoclonal rat anti-mouse 
A6 antibodies (a gift from Dr. Valentina Factor, NIH) diluted 1:10 and incubated 
overnight at 4°C. The next day, peroxidase was blocked with 3% hydrogen peroxide for 
10 minutes before adding secondary goat anti-rat biotinylated antibody for 60 minutes at 
room temperature (1:100 dilution, Jackson Immuno Research). Extravidin-peroxidase 
(1:400 dilution; Sigma) was added for 30 minutes at room temperature, followed by 
color development with 3,3’-diaminobenzidine (DAB), counterstaining with hematoxylin, 
dehydration in ethanol and xylenes, and mounting in Permount. Between each step, 
tissues were rinsed in PBS. Labeling for wide spectrum cytokeratin (CK) was done 
identically to A6 staining except for the following: 1) antigen retrieval was done with 
trypsin but without addition of proteinase K; 2) primary antibody was rabbit anti-bovine 
cytokeratin (1:100 dilution, Dako).  Albumin, Hep-Par1 and GST-P (hepatocytes). 
Stainings were done identically to that described above for cytokeratin and A6, except 
7 
 
 
that 1) antigens were retrieved by boiling tissues (at 95-100ºC) in citrate buffer (pH 6) 
for 40 minutes and 2) Hep-Par1 and GST-P incubation with primary antibody was for 1 
hour at room temperature. The primary antibodies used were: rabbit anti-albumin, 1:100 
dilution (Sigma), rabbit anti-Hep-Par1, 1:80 dilution (Sigma) and anti-GST-P (placental 
glutathione S-transferase), 1:1000 dilution (MBL Co.).   
 Histochemistry. Mucicarmine staining was done on formalin fixed and paraffin 
embedded tissues cut at 5 µm. Slices were stained with hematoxylin for 10 minutes, 
washed and then soaked in muciramine solution (Sigma) for 1 hour at room 
temperature. Slides were then washed, counterstained in metanil yellow for 1 min, 
dehydrated and coverslipped in Permount. GGT (γ-glutamyl transpeptidase) 
histochemistry was done on frozen sections cut at 10 µm and fixed in cold acetone for 
10 minutes. They were then incubated in solution containing GGT substrate GMNA (L-
glutamic acid γ-(4-methoxy-ß-naphtylamide, Sigma), glycyl-glycine and Fast Blue BB 
salt for 20 min and stained in cupric sulfate for 2 min as described (14).    
 AFB1-DNA adduct analysis.  AFB1-N7-guanine adducts were measured in liver 
tissue using liquid chromatography-electrospray ionization tandem mass spectrometry 
as previously described (7).  Values were expressed as pmol/mg DNA. 
 Liver extract preparation.  Four groups of 3-month old C57Bl/6J mice representing 
WT male, WT female, GSTA3 KO male, and GSTA3 KO female (7 animals each) were 
sacrificed and the livers saline perfused, removed, and snap frozen in liquid nitrogen.  
At the time of processing, the frozen tissues were added to ice-cold lysis buffer (Cell 
Signaling, Danvers, MA) containing phosphatase and protease inhibitors and sonicated, 
centrifuged 20 minutes at 11,000 x g, and the supernatant extract collected.   
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 GST purification.   The liver 11,000 x g supernatants were chromatographed on a 
glutathione-agarose affinity column and bound GST proteins eluted, all according to the 
manufacturer (Novagen/EMD Millipore, Billerica, MA).  These samples were then 
concentrated using Amicon Ultra 4 columns (EMD Millipore) and protein concentration 
in these concentrates determined using the BioRad protein reagent (BioRad).   
 GST enzyme activity.   The GST enzymatic activity in the glutathione-agarose 
affinity purified liver supernatants were quantified using a GST assay kit, which utilizes 
1-chloro-2,3-dinitrobenzene as the substrate, according to the manufacturer (Sigma).  
These analyses were carried out using 0.2 µg protein per well after first establishing that 
this was in the linear portion of velocity curve.   
 F2-Isoprostane and isofuran oxidation marker analyses. Snap frozen liver 
tissues were analyzed by the Vanderbilt University Eicosanoid Core Laboratory using 
gas chromatography and mass spectroscopy as previously described (15).  Values 
were expressed as ng per gram liver tissue (ng/g). 
 Western blot analyses.   Equal amounts of protein (2.5 µg) per well were 
electrophoresed on a 14% SDS PAGE gel, transferred to nitrocellulose, and allowed to 
react with various GST antibodies (16).  These antibodies included 1:2,000 dilutions of 
rabbit antiserum against GSTA3, GSTA4, and GSTM5 as well as 1:3,000 dilutions of 
rabbit antiserum against GSTM1 and GSTP1.  Antisera probings were successive and 
separated by blot stripping to remove cross-reacting antibodies from the previous 
reaction using the Restore Plus Western blot stripping buffer (ThermoFisher, Waltham, 
MA).  After incubation with primary antibody and appropriate washes to eliminate non-
specific binding, the immobilized protein on the blots were allowed to react with a goat 
9 
 
 
anti-rabbit secondary HRP conjugate (1:2000) and washed again. The antibody signal 
was then captured using the Western lightning plus kit substrate (PerkinElmer, 
Waltham, MA) and the resultant chemiluminescent signal was captured by film, and 
quantified using ImageJ software.  
Cytochrome P450 and epoxide hydrolase analyses.   Western blots were 
exposed to primary antibodies against CYP1A2 (Santa Cruz Biotechnology, Dallas, TX), 
CYP3A11 (EMD Millipore), and microsomal epoxide hydrolase (Detroit R&D, Detroit, 
MI), and then processed as described above.  Signals were normalized to VDAC1 after 
stripping. 
Liver function analysis.  Aspartate transaminase (AST) was measured from serum 
samples taken at each time point as described (17) by the Molecular Diagnostics 
laboratory of Wadsworth Center using a Roche cobas 6000 analyzer.   
Statistics.  Data are reported as the mean +/- SEM with statistical significance 
defined as p<0.05 using a 2-tailed Student's t- test.    
 
Results 
Tumor formation in GSTA3 KO mice in response to AFB1 exposure.  Male and 
female mice were treated once per week with 0.5 mg/kg AFB1 for 12 (4 males, 6 
females) and 24 (5 males, 7 females) weeks and livers analyzed at 12 and 6 months, 
respectively, after the last AFB1 injection.  Mice that received 24 injections had a rest 
period of 8 weeks between the first 12 and last 12 injections.  All mice had grossly 
distorted livers, with cysts, nodules and tumors, with 24 injections resulting in more 
numerous and coalescing lesions than 12 injections (Figure 1A-D). Histologically, these 
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lesions are hepatocellular nodules (mostly of the early or Becker type 1 grade) (18), 
cholangiomas and cholangiocarcinomas (Figure 1E-M). Two serial sections of the 
largest diameter of each lobe were examined.  All examined mice have multiple 
cholangiomas; 2/4 males and 3/6 females given 12 injections, and 3/5 males and 7/7 
females given 24 injections had cholangiocarcinomas; and 2/4 males and 3/6 females 
given 12 injections and 5/5 males and 7/7 females given 24 injections have from one to 
three Becker type 1 hepatocellular nodules (and only occasionally a Becker type 2 or 3 
nodule). There are no hepatocellular carcinomas (Becker type 4 nodules) or distant 
metastases (e.g. lung). There is normal liver histology in all vehicle (DMSO) treated 
control mice (5 males and 5 females, 12 and 24 weekly injections). In addition to their 
typical morphology, the identity of cholangiomas and cholangiocarcinomas is confirmed 
by cells staining positive for pan-CK and for mucin (mucicarmine stain) (Figures 1J and 
1K). Hepatocellular nodules are best identified by morphology. Some hepatocyte foci 
are positive for GGT (Figure 1L), but so are some small cholangiomas as well as many 
individual cells, hepatocytes and, based on typical shape and proximity to cholangiomas 
and cholangiocarcinomas, oval cells.  GST-P also does not stain hepatocellular 
nodules, only some individual hepatocytes and some small foci of hepatocytes (Figure 
1M). Anti-albumin and anti-Hep-Par1 immunohistochemistry label most normal 
hepatocytes but nodules show mixed positive and negative cells (data not shown).  
Histologic effects of AFB1 treatment in GSTA3 KO mice. The detailed 
histopathologic changes seen over time during treatment of male and female GSTA3 
KO mice with AFB1 (3-5 mice/time point) are shown in Figure 2 using a protocol of 
weekly (1-12) 0.5 mg AFB1/kg administration. Tissues from 4 to 8 mice of both sexes 
11 
 
 
were evaluated for each time. Megahepatocytes were counted in 10 random 200X fields 
and expressed as number of cells per field. Due to the difficulty in accurately counting 
oval cells, as they can show as either single cells or as part of ductules, they were 
scored (from 0 to 4+) according to the following criteria:  Grade 0 - there are less than 5 
oval or duct-like cells beyond the immediate periportal zone; Grade 1+ -  up to 20 oval 
cells are seen extending into the first 1/3rd of the liver lobule but not in all lobules; 
Grade 2+ - 20 to 100 oval cells extend into the mid-lobule but not to the central vein; 
Grade 3+ - 100-300 oval cells extend to the central vein in essentially all lobules, but 
many hepatocytes are still seen; Grade 4+ - Greater than 300 oval cells make up most 
of the cells of the lobule. At 1-3 weeks, oval cell proliferation (0-1+) is seen (Figure 
2B,C) and this increased throughout the period of observation as compared with 
untreated mice (Figure 2A). At 3-5 weeks there is massive hepatocyte microvesicular 
lipidosis, involving the entire lobule in all mice (Figure 2D) and oval cells are prominent 
in both males and females (2+ to 4+). No megahepatocytes are present. By 6-8 weeks, 
OC proliferation continues to be high (grades 2+ to 4+) but the microvesicular fatty 
change is replaced by large hepatocytes (megahepatocytes) (Figure 2E) with 
eosinophilic cytoplasm and large nuclei (males: 1.6±0.7/field; females: 2.0±0.8/field) and 
nuclear inclusions are first seen (Figure 2F). At 9-12 weeks, megahepatocytes continue 
to be prominent (males: 1.7±2.4/field; females: 1.3±0.9/field) as are nuclear inclusions. 
There are now cholangiomas (Figure 2G) and small grade I nodules in a few mice 
(Figure 2H). At 3-4 months after last (12th) weekly AFB1, megahepatocytes are spread 
throughout most of the parenchyma (males: 13.3±9.6/field; females: 9.6±14.0/field) with 
prominent nuclear inclusions. There are multiple peripheral cholangiomas almost all 
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mice.  At this time, only half of both males and females had one or two type 1 
hepatocellular nodules.  
Female GSTA3 KO mice are more sensitive to acute AFB1 exposure than male 
GSTA3 KO mice. To assess and compare the response of our KO mice to acute AFB1 
in both genders, female and male GSTA3 KO mice were injected i.p. with a single dose 
of AFB1 and 4 to 9 mice euthanized at 5, 10, 15, 30, 60 and 90 days after 
administration of the mycotoxin. Oval cell proliferation was quantified by grading the 
tissues from 0 to 4+, as described above.  At the highest single AFB1 dose in female 
KO mice (1.0 mg/kg), there is fat accumulation, cell necrosis and swelling after 5 days 
(Figure 3B) and oval cells are present in small numbers (graded from 0 to 1+; grade 
average 0.7±0.4 per mouse). OCs increase significantly by day 10 (2+ - 4+; grade 
average 2.8±1.4) (Figure 3C,D) and day 15 (1+ - 3+; grade average 1.8±0.7) (Figure 
3E) after administration of AFB1. The reduction in numbers of OCs at day 15 compared 
to day 10 is due to greater variability among 8 mice examined at this time point. OCs 
peak again around day 30 (2+ - 4+; grade average 2.9±0.8) (Figure 3F) and then 
decrease between days 60 (0 – 1+; grade average 0.6±0.6) and 90 (almost no OC 
present in any animal). The OCs typically form single files or narrow ductules around 
hepatocytes and extend throughout the liver lobule from the portal to the pericentral 
zone. They stain positive with antibodies against oval cell/bile duct specific markers A6 
(Figure 3G) and pan-cytokeratin (PanCK; Figure 3H). 
 In contrast to females, male GSTA3 KO mice have no liver injury after 1.0 mg/kg 
AFB1 injection and no OC regenerative response (Figure 3I). Following repeated 
dosing, however, the livers of GSTA3 KO males display similarly extensive OC 
13 
 
 
proliferation as did females. Female and male GSTA3 KO mice injected with vehicle 
(DMSO; Figure 3A for female) and WT mice injected with the same doses of AFB1 have 
no injury (data not shown for WT mice). 
Female KO mice exhibit higher AFB1-DNA adduct levels.  Previous studies 
demonstrated a striking increase in the levels of AFB1-N7-guanine adducts in GSTA3 
KO versus WT male mice (7).  In the present study, these previous analyses were 
extended to assess comparative gender response.  Analyzing adducts as previously 
described (7), female KO mice develop 3.5-fold more adducts than male KO mice 
(183.2 pmol/mg DNA vs. 52.7 pmol/mg DNA) when given 0.87 mg/kg AFB1 by gavage 
(Figure 4).  
KO mice, especially females, exhibit decreased GST isoform expression.  To 
further investigate the basis behind the observed gender differences, we examined the 
possible compensatory response of other GST subunits in male versus female KO mice 
using glutathione affinity column-purified samples and Western immunoblotting.  As 
expected, no GSTA3 was detected in livers of KO mice (Figure 5A).  We also examined 
GSTP1, GSTM1, GSTM5 and GSTA4 levels in mouse liver.  Overall, no compensatory 
up-regulation of these other GST isoforms was observed in GSTA3 KO mice. 
Remarkably, an overall reduction in one of the most abundant mouse GST subunits 
(GSTP1) was observed in KO livers (Figure 5B). In addition, we discovered a greater 
decrease in GSTP1 in KO female than in KO male mice (Figure 5B. Note: this was 
further confirmed by running these samples on the same blot; data not shown). 
Statistically significant reductions in the expression of GSTM5 (Figure 5D) but not 
GSTA4 (Figure 5E) were detected in both male and female KO as compared with WT 
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mice. Thus no overall GST subunit compensatory increase occurs in GSTA3 KO mouse 
liver.  In fact, there is a reduction of the GSTP1 subunit, which is even more pronounced 
in female KO mice than in male KO mice.  
CYP1A2 but not CYP3A11 or microsomal epoxide hydrolase levels were 
increased in male KO mice.  We also assessed the levels of cytochrome P4501A2 
(CYP1A2), P4503A11 (CYP3A11, the main mouse equivalent of human CYP3A4),  and 
microsomal epoxide hydrolase, major proteins involved in aflatoxin metabolism as part 
of phase 1 response that regulate aflatoxin epoxide levels (19-21) in liver extracts. 
Levels of CYP1A2, which contributes to aflatoxin epoxide formation, were significantly 
higher in KO males as compared with WT males or either female genotype (Figure 5F). 
However, this increase is not likely to be compensatory since a compensatory effect 
would instead be expected to be a reduction of CYP1A2 in KO mice as a way of 
reducing substrate activation.  This CYP1A2 signal was also much more variable than 
other proteins analyzed thus far. Levels of cytochrome CYP3A11, which also 
contributes to aflatoxin epoxide formation, also exhibited significant variability but 
statistically, did not show a difference in WT versus KO or in male versus female mice 
(Figure 5G). In addition, there were no differences in the levels of microsomal epoxide 
hydrolase, an enzyme that can hydrolyze and detoxify AFB1, in WT versus KO or in 
male versus female mice (Figure 5H).   
 Glutathione S-transferase (GST) activity is higher in WT males.  Total GST 
activity was assessed in glutathione affinity column-purified eluate.  Values were similar 
in males and females except for a significantly increased level in WT males (Figure 5I). 
This increase in GST activity in livers of WT male mice likely reflects both the presence 
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of GSTA3 (versus knockouts) as well as much higher levels of GSTP1 in WT males 
versus KO males or WT and KO females.  Importantly, and specific to aflatoxin, we 
have also previously reported that urinary excretion of AFB1-NAC, a product of 
glutathione adduction  of AFB1 that is mediated by GSTs, is dramatically reduced in 
GSTA3 KO versus WT mice (22).   
KO mice show increased oxidation in response to CCl4.  Oxidative stress 
damage was also assessed in WT versus KO mice based on the fact that many liver 
carcinogens (including AFB1) are also oxidants (23-25), and also because GSTA3 
exhibits in vitro peroxidase activity toward the substrate cumene hydroperoxide (26).  
The relative importance of GSTA3 in a cellular antioxidant defense has never been 
directly tested in vivo, and as such, our KO mice represent a first opportunity to address 
this.  In order to readily assess and compare strong enough signals, we used the potent 
liver oxidant carbon tetrachloride (CCl4), which was also used for a similar purpose to 
assess GSTA4 peroxidase activity in vivo (27).  Mice were administered 1 ml/kg CCl4 
and at appropriate time points, the lipid peroxidation markers F2-isoprostanes and 
isofurans were measured.  As shown in Table 1, almost all F2-isoprostane and isofuran 
levels are greater – in some cases statistically significantly so – in GSTA3 KO versus 
WT mice following exposure to CCl4. Overall, there is a modest increase in F2-
isoprostane and isofuran oxidation markers in KO mice.  This also confirms predicted 
GSTA3 peroxidase activity in vivo for the first time.   
Regarding gender-dependent sensitivity, there were greater constitutive as well as 
induced F2-isoprostane levels in female GSTA3 KO mice at 24 hours compared with 
male KO mice.  This also occurred at 24 hours for isofuran. However, the reverse 
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occurred at 8 hours.  Overall, we conclude that there is a modest increase in oxidative 
stress damage in female- as compared to male-KO mice.  
There were also significant changes in the ratios of F2-isoprostane to isofuran levels 
at 2 and 8 hours independent of genotype and gender. Interestingly, levels of F2-
isoprostanes and isofurans are much greater two hours after CCl4 exposure when 
compared with the commonly used 24 hour time point, suggesting that a 24 hour time 
point is less sensitive if not inadequate for assessing CCl4-stimulated oxidative damage 
in vivo. 
Hepatocellular damage increases with exposure time to CCl4, and does not 
correlate with peak oxidative damage.  The release of the liver function marker AST 
into serum was also evaluated after CCl4 exposure.  As shown in Table 1, a statistically 
significant increase in serum AST occurred at 8 hours and especially 24 hours.  These 
results are consistent with the damaging effects of CCl4, since AST is a liver damage 
marker.  Interestingly, AST levels did not correlate with lipid peroxidation markers F2-
isoprostanes and isofurans (Table 1).  Specifically, lipid peroxidation peaked at 2 hours 
and fell almost completely back to control levels after 24 hours of CCl4 exposure, 
whereas AST release was maximal at 24 hours.  
 
 
Discussion 
 Since AFB1 is a major risk factor for HCC in humans, GSTA3 knockout (KO) mice 
were constructed to provide a mouse model for the study of AFB1 carcinogenesis.  As 
hoped, these mice exhibited acute cytotoxicity and genotoxicity upon exposure to AFB1, 
establishing these knockouts as a useful model to study the interplay of risk factors 
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leading to liver injury and cancer development in humans (7). Here, we extend these 
studies to better understand this mouse model and to provide new insights into human 
liver cancer.    
 Using various aflatoxin and oxidative stress protocols, we assessed 
histopathological changes, tumor formation, key biochemical changes and gender 
response in detail.  Most notably, there is extensive oval (OC) proliferation which 
increases over time.  This is followed by microvesicular lipidosis, megahepatocyte-, 
nuclear inclusion-, and cholangioma-, and small nodule-formation, providing detailed 
morphological characterization of pathological responses to AFB1.  After long term 
exposure to AFB1 all mice display severely distorted livers with cysts, nodules and 
tumors, identified histologically as hepatocellular nodules and cholangiomas and 
cholangiocarcinomas. Because GSTA3 KO are the first, and only, mice made that are 
sensitive to AFB1, no protocol was available as a guide on the dose and regimen of 
AFB1 to use. The commonly used regimen of AFB1 exposure in rats, daily injections for 
4-8 weeks, results in hepatocellular foci and HCC, without cholangiomas (28,29). The 
GSTA3 KO mice cannot survive a similar daily regimen, but the total dose of AFB1 
given to mice (6-12 mg/kg) in our long term exposure is similar to that used in rats. The 
association of AFB1 and development of CCA has been reported before. For example, 
chronic exposure of hamsters to AFB1 results in tumors of CCA and mixed HCC/CCA 
types (30). Also, rats exposed to AFB1 develop CCA (or mixed hepatocholangiocellular 
carcinomas) if AFB1 is combined with agents that induce OC proliferation (a carcinogen 
2-acetylaminofluorene + partial hepatectomy) (31). The association between 
proliferating oval cells and resulting cholangiocarcinomas, and suggestion of a possible 
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causative link between the two, has been reported in other models of liver cancer in rats 
(32,33), mice (34) and hamsters (35) as well as in humans (36,37).   
 The OC response in KO mice – especially female - was much greater and different 
in growth pattern than in other mouse models reported in the literature. There are 
several ways to induce OCs in mouse liver, from employing certain chemicals to 
spontaneous induction in transgenic or knockout mice. However, the majority of reports 
rely on two models: DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) supplemented diet 
(38,39), and less frequently, CDE (choline deficient/ethionine) supplemented diet 
(40,41). Both of these models induce a relatively low level ductular-type OC response, 
do not induce tumors, and neither agent is relevant for human health. In contrast, the 
OC proliferation that we describe here in GSTA3 KO mice is associated with the 
clinically relevant environmental carcinogen (AFB1), is sustained over many weeks, is 
much more severe, is morphologically different from DDC or CDE (not ductular), and 
may result in development of neoplastic liver lesions. Thus, our GSTA3 KO mouse 
represents a valuable model for studying the role of OCs in normal liver regeneration 
and in liver tumor development. 
 In essentially all susceptible species studied including humans, rats and trout, males 
have a much greater toxic and carcinogenic susceptibility to AFB1 than females (1). 
Thus, we expected a similar gender effect in GSTA3 KO mice.  Surprisingly, however, 
male KO mice exhibited  significantly less acute liver injury, OC proliferation, and AFB1-
DNA adduct levels than female KO mice when exposed to a single low dose of AFB-1.  
We considered the possibility that male KO mice have a greater compensatory 
response to loss of GSTA3 than female KO mice, and thereby express higher levels of 
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other transferases.  However, instead of an increase in other GST subunits, there was 
an overall reduction of the most abundant isoforms (GSTP1 and GSTM1) in both male 
and female KO mice.  Additionally, there was lack of a significant epoxide hydrolase, 
CYP1A2, CYP3A11 or GST specific activity compensatory response in the KO mice 
although an increase of CYP1A2 was seen in male but not female mice.  Overall, these 
results provide evidence that initial susceptibility to AFB1 is greater in female mice, 
however this increased female susceptibility disappears with repeated exposures.   
 Besides detoxifying AFB1, GSTA3 is notable for possessing glutathione peroxidase 
activity toward organic hydroperoxides (26). GSTA3 has a functional antioxidant 
response element (ARE) in its gene promoter (42), and is induced in a nuclear factor-
erythroid 2 p45-related factor 2 (Nrf2)-mediated fashion following treatment with 
phenolic antioxidants or cytoprotective compounds. The relative importance of GSTA3 
in a cellular antioxidant defense has never been directly tested in vivo.  AFB1 exposure 
leads to a pro-oxidant state and redox analysis is directly relevant to AFB1 
carcinogenesis (21-24). Pro-oxidants are known mutagens (43-45), and thus may 
contribute, in addition to AFB1-DNA adducts, to AFB1 liver carcinogenesis. We 
assessed oxidative damage in GSTA3 KO mice using CCl4, which is well known for its 
ability to produce centrolobular necrosis of the liver; has been used extensively in 
studies of the proliferation of hepatocytes after liver injury (46) including in our 
laboratory (47). It has been used for a similar purpose to assess GSTA4 peroxidase 
activity in vivo (27). CCl4 liver injury is thought to mainly involve generation of reactive 
oxygen species (ROS), including lipid hydroperoxides (48), and has been frequently 
used as an inducer of ROS in mice. Overall, we observed a modest increase in F2-
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isoprostane and isofuran oxidation markers in KO mice, providing evidence – for the 
first time – that GSTA3 possesses peroxidase activity in vivo.  We also observed 
greater F2-isoprostane and isofuran in females than males.  The GST A4-4 isoenzyme 
also reduces organic hydroperoxides, and its expression has been linked to AFB1 
toxicity in mice (49). Mice lacking GSTA4 exhibit increased levels of 4-hydroxynonenal 
(4-HNE) as compared with their WT counterparts (27,49).  Most of the increase in 4-
HNE was present constitutively in these previous studies, with little increase after 
oxidative stress. Conversely, we observed significant differences between WT and KO 
mice in the oxidative marker levels under constitutive conditions and also after 
treatment with CCl4.  
 Interestingly, our detailed time course analysis found peak oxidation at time points 
that were quite distinct (i.e., much earlier) from published studies. These results indicate 
the best time points to assess oxidation using CCl4, and perhaps other oxidants; not just 
for our study but also as a guide for other researchers in the field.  Also of interest was 
the difference between peak oxidation (2 hours) and peak liver function enzyme release 
(24 hours).  The latter 24-hour peak might be one reason why researchers have chosen 
to assess oxidative damage after 24 hours, but we demonstrate here that the two 
effects are temporally distinguishable.  The long delay between peak oxidative damage 
and peak serum AST also suggests that lipid peroxidation leads to subsequent and 
time-consuming stress response signaling before eventual AST release. This 
interpretation is consistent with a growing list of lipid peroxidation products such as 4-
HNE that have been identified as important cell signalers (50).   
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 In conclusion, we have extended characterization of our novel GSTA3 KO mouse 
model. This includes assessing the sequence of events leading up to and including 
histopathological changes, tumor formation, biochemical changes and gender response 
following AFB1 treatment as well as the contribution of oxidative stress. Our results also 
provide evidence that initial susceptibility to AFB1 is greater in female mice, in contrast 
to the known higher rate of liver cancer in males in humans, and that oval cell response 
and GSTA3 peroxidase activity may influence susceptibility to cancer development.   
 The repeated long term exposure of the GSTA3 KO mice to AFB1 leads to marked 
long-lasting proliferation of OCs and eventually hepatocellular nodules, cholangiomas 
and CCAs. Exposure of rats to diethylnitrosame does not induce proliferation of OCs 
and results in HCC (8,9). In other rat models with extensive OC proliferation early HCC 
appear later after the carcinogen exposure has been discontinued (8,9). This may allow 
OC differentiation to hepatocytes and then these “induced” hepatocytes form HCC. 
Thus, in hepatocarcinogenic models where OC proliferation is greatest and hepatocyte 
proliferation is inhibited, it appears that CCA is induced rather than HCC.  
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Table 1.  F2-isoprostane, isofuran and AST levels in male and female wild type and 
GSTA3 knockout mice following exposure to carbon tetrachloride 
 
Marker 
 
CCl4 (hrs) 
 
Male 
 
Female 
  WT KO WT KO 
Isoprostane 0  2.26 +/- 0.20 
 
2.41 +/- 0.26 
 
1.70 +/- 0.03 
 
 
3.23 +/- 0.12*,** 
  2 hours 50.70 +/- 2.66 53.69 +/- 2.28 
 
 
51.46 +/- 4.61 56.58 +/- 4.7 
 
 
 8 hours 7.87 +/- 1.17 
  
9.44 +/- 0.85 
 
 
6.05 +/- 0.34 10.42 +/- 0.86* 
 
 
 24 hours 2.51 +/- 0.08 2.54 +/- 0.27 
 
 
3.48 +/- 0.32 5.47 +/- 1.19** 
Isofuran 0  2.82 +/- 0.13 
 
 
2.73 +/- 0.29 
 
2.05 +/- 0.13 
 
 
3.28 +/- 0.21* 
  2 hours 17.89 +/- 1.55 
 
21.16 +/- 2.02 
 
 
18.89 +/- 2.09 
 
22.50 +/- 1.49 
 
 
 8 hours 5.82 +/- 0.45 
  
9.26 +/- 0.92* 
 
 
3.36 +/- 0.09 
 
5.31 +/- 0.55*,** 
 
 
 24 hours 3.04 +/- 0.20 2.19 +/- 0.24 
 
 
2.96 +/- 0.46 4.47 +/- 0.82** 
AST 0  176 +/- 26 
 
 
217 +/- 32 
 
221 +/- 39 
 
 
250 +/- 37 
  2 hours 264 +/- 23 
 
202 +/- 23 
 
 
214 +/- 46 
 
475 +/- 135** 
 
 
 8 hours 670 +/- 204* 
  
489 +/- 65* 
 
 
693 +/- 34* 
 
848 +/- 173* 
 
 
 24 hours 3683 +/- 1117* 2494 +/- 1062* 
 
 
3327 +/- 716* 3552 +/- 661* 
 
F2-isoprostane and isofuran data are expressed as ng/g liver tissue, and AST as 
units/liter serum.  All data are presented as means +/- SEM (N=5-7).  * Significant 
difference between WT and KO at each given time point when comparing F2-
isoprostane and isofuran data, and significant difference between Control and 8 hour or 
24 hour time points when comparing AST data, both using a 2-tailed Student's t- test at 
p<0.05.  ** Significant difference between male and female KO at each given time point 
using a 2-tailed Student's t- test at p<0.05.   
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Figure legends 
    
 Figure 1. Gross (A-D) and microscopic (E-L) lesions in GSTA3 KO mice treated 
with weekly (12 or 24) AFB1 injections (0.5 mg/kg).  A. Normal (control) liver, male 
mouse, 24 injections of vehicle (DMSO) (L, M, R, C – left, middle, right and caudate 
lobes). B. Cysts (short arrows in middle lobe) and tumor (long arrow in left lobe), male, 
12 injections. C. Multiple nodules (short arrows) and tumors (long arrows in left and 
right), male, 24 injections. D. Entire liver composed of coalescing nodules (arrows), 
female, 24 injections.  E, F. Multifocal cholangiomas (arrows), male, 24 injections, H&E 
(40X). Cholangioma in F is a higher magnification (200X) of a rectangle in E.  
G. Cholangiocarcinoma (arrows), female, 24 injections, H&E (200X). H, I. Becker type 1 
hepatocellular nodule (arrows), female, 24 injections, H&E (40X). I is a higher 
magnification (200X) of a rectangle in H. J. Pan-CK positive cholangioma cells (arrows), 
female, 24 injections (200X). K. Mucicarmine stained mucin in cholangiocarcinoma, 
male, 24 injections (200X). L. GGT positive focus of hepatocytes (arrow), female, 12 
injections (40X). M. GST-P stained small focus of hepatocytes (arrow) and individual 
cells, female, 24 injections (200X). 
 
 Figure 2.  Histologic effects of AFB1 treatment (0.5 mg/kg) in GSTA3 KO mice.  
A-H; H&E stained images. A. Liver of a male mouse given DMSO once a week for 13 
weeks (200X). B-H livers after weekly injections of 0.5 mg/kg AFB1. B. Grade 2 OC 
proliferation extends to mid-zone (200X). C. Grade 4 OC proliferation extends from 
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portal (P) to central (C) zone (200X). D. Microvesicular fatty change (200X). E. 
Megahepatocytes (examples shown with arrows) (200X). F. Nuclear inclusions 
(examples shown with arrows) (400X). G. Cholangiomas (200X). H. Nodule (Becker 
grade I) (40X). 
 
 Figure 3.  Oval cell proliferation in liver in response to acute AFB1 exposure (1 
mg/kg).  A-F and I; H&E staining.  G and H; A6 and Pan-CK immunostaining, 
respectively.   A. KO female mouse liver, untreated. P=portal vein branch, C=central 
vein branch (200X).  B. KO female mouse, 5 days after AFB1. Acute injury with cell 
necrosis and swelling visible (100X). C, D. KO female mouse, 10 days after AFB1. 
Numerous oval cells are visible (arrows in D). D is a higher magnification (400X) of the 
dashed line rectangle in C (200X).  E. KO female mouse, 15 days after AFB1. Oval cells 
are seen throughout the lobule (arrows) (200X).  F. KO female mouse, 30 days after 
AFB1. Numerous oval cells are still present (arrows) (200X).  G. KO female mouse, 15 
days after AFB1. Oval cells are A6-positive (arrows) (200X).  H. KO female mouse, 30 
days after AFB1. Oval cells are Pan-CK-positive (arrows) (200X).  I. KO male mouse, 
10 days after AFB1. No oval cells are seen at any time after AFB1 (200X).  
 
 Figure 4.  AFB1-DNA adduct formation in liver in response to acute AFB1 
exposure.  Mice were given 0.87 mg/kg AFB1 in DMSO or DMSO only (control) by 
gavage, and livers collected 2 hours later. WT-F, wild type female; WT-M, wild type 
male; KO-F, knockout female; KO-M, knockout male.  Data are expressed as mean ± 
SEM (N=5).  *Significant difference using a two-tailed Student’s t-test at p<0.05.   
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 Figure 5.  Gender and genotype comparison of GSTs and aflatoxin 
metabolizing proteins.  Four groups of three month old C57Bl/6J mice representing 
WT males, WT females, KO males, and KO females (7 animals for each group) were 
sacrificed and livers removed and extracts prepared.  For GST isoform analyses, these 
extracts were further chromatographed on a glutathione affinity column.  Equal amounts 
of purified GST-containing proteins (A-E) or extracts (F-H) were then electrophoresed 
and analyzed by Western immunoblotting.  A. GSTA3; B. GSTP1; C. GSTM1; D. 
GSTM5; E. GSTA4; F. CYP1A2; G. CYP3A11; H. epoxide hydrolase. Blots were then 
stripped and reprobed with- and data normalized to- VDAC1 loading control. 
Quantitation of blot signals was carried out using ImageJ. I. GST activity in WT and KO 
mouse livers. Samples were prepared as described above and GST enzyme activity 
measured in the affinity purified extracts. White plot, wild type mice; grey plot, knockout 
mice. Data are expressed as mean ± SEM (N=7).  *Significant difference using a two-
tailed Student’s t-test at p<0.05.     
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